BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Apr 27, 2026; 18(4): 116371
Published online Apr 27, 2026. doi: 10.4240/wjgs.v18.i4.116371
Table 2 Comparative analysis of surgical indicators, health economics indicators, efficacy evaluation indicators, and postoperative medical management

EFR group (n = 98)
STER group (n = 99)
LMIS group (n = 345)
H/χ2 value
P value
Surgical indicators
Operative times [M (Q1, Q3), minutes]44.5 (27.0, 78.0)59.5 (33.0, 91.0)87.0 (60.0, 115.0)73.33< 0.001
Blood loss [M (Q1, Q3), mL]5.0 (3.0, 8.0)3.0 (2.0, 5.0)20.0 (10.0, 50.0)251.67< 0.001
Health economics indicators
Hospital stay [M (Q1, Q3), days]8.0 (7.0, 9.0)8.0 (7.0, 9.0)9.0 (7.0, 11.0)6.530.038
Surgical costs [M (Q1, Q3), CNY]16753.4 (12914.0, 24603.0)13963.0 (9477.1, 16944.6)25127.8 (19532.8, 32571.5)139.62< 0.001
Surgical costs [M (Q1, Q3), USD]2435.1 (1877.0, 3576.0)2029.5 (1377.4, 2462.9)3652.2 (2839.1, 4734.2)139.62< 0.001
Efficacy evaluation indicators
Overall postoperative adverse event incidence, n (%)34 (34.7)49 (49.5)2 (0.6)171.89< 0.001
Postoperative abdominal pain incidence, n (%)13 (13.3)26 (26.3)1 (0.3)81.98< 0.001
Postoperative fever incidence, n (%)28 (28.6)42 (42.4)0 (0.0)149.17< 0.001
Postoperative hematemesis or melena incidence, n (%)2 (2.0)2 (2.0)0 (0.0)8.150.017
Postoperative medical management
Duration of nasogastric tube placement [M (Q1, Q3), days]0.0 (0.0, 4.0)0.0 (0.0, 0.0)1.0 (1.0, 3.0)89.92< 0.001
Method of PPI administration, n (%)117.26< 0.001
No1 (1.0)0 (0.0)10 (2.9)
Intravenous drip66 (67.3)81 (81.8)335 (97.1)
Intravenous pumping31 (31.6)18 (18.2)0 (0)
PPI use duration [M (Q1, Q3), days]6.0 (5.0, 7.0)6.0 (5.0, 7.0)4.0 (3.0, 5.0)148.95< 0.001
Types of anti-infective agents, n (%)374.83< 0.001
No1 (1.0)0 (0.0)3 (0.9)
Monotherapy with a first-line or second-line antimicrobial33 (33.7)18 (18.2)332 (96.2)
Combination therapy with metronidazole for anaerobic coverage47 (48.0)71 (71.7)0 (0.0)
Escalation to higher-level antimicrobials17 (17.3)10 (10.1)10 (2.9)
Duration of antimicrobial treatment [M (Q1, Q3), days]5.0 (4.0, 6.0)5.0 (4.0, 6.0)4.0 (3.0, 5.0)68.45< 0.001
Time to resume oral intake [M (Q1, Q3), days]6.0 (5.0, 7.0)5.0 (4.0, 6.0)2.0 (1.0, 3.0)283.10< 0.001


Write to the Help Desk